Igc Pharma (NYSEMKT: IGC)
Igc Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Igc Pharma Company Info
IGC Pharma, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
News & Analysis
Marijuana Train Wreck: These 19 Pot Stocks Lost 20% (or More) in October
A closer look at why most weed stocks went up in smoke despite Canada legalizing recreational cannabis.
This Pot Stock Just Got Booted Off the NYSE
From smoking-hot marijuana stock to smoldering mess in about a month.
Cannabis-Infused Beverages: 3 Things You May Not Realize
CBD-infused beverage stocks are on fire, but can they meet lofty expectations?
Why Marijuana Stocks Tilray, New Age Beverages, and India Globalization Capital Slumped Today
Find out why investors soured on cannabis companies.
The 3 Most Dangerous Marijuana Stocks
Though the cannabis industry is budding, these pot stocks are at high risk of going up in smoke.
This New Cannabis Craze Has Made Early Investors Rich
Forget about smoking pot -- these stocks are smoking even if their products aren't.
Why Century Aluminum, Select Income REIT, and India Globalization Capital Slumped Today
Find out which of these stocks suffered from potentially dilutive stock offerings.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.